Advertisement

Breast Cancer Research and Treatment

, Volume 146, Issue 3, pp 515–523 | Cite as

RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase

  • Hong Hu
  • Jun Wang
  • Akash Gupta
  • Ali Shidfar
  • Daniel Branstetter
  • Oukseub Lee
  • David Ivancic
  • Megan Sullivan
  • Robert T. ChattertonJr.
  • William C. Dougall
  • Seema A. Khan
Preclinical study

Abstract

The receptor activator of nuclear factor-κB ligand (RANKL) acts as a paracrine factor in progesterone-induced mammary epithelial proliferation and tumorigenesis. This evidence comes mainly from mouse models. Our aim was to examine whether RANKL expression in human normal and malignant breast is under the control of progesterone throughout the menstrual cycle. Breast epithelial samples were obtained by random fine needle aspiration (rFNA) of the contralateral unaffected breasts (CUB) of 18 breast cancer patients, with simultaneous serum hormone measurements. Genes correlated with serum progesterone levels were identified through Illumina microarray analysis. Validation was performed using qRT-PCR in rFNA samples from CUB of an additional 53 women and using immunohistochemistry in tissue microarrays of 61 breast cancer samples. Expression of RANKL, DIO2, and MYBPC1 was correlated with serum progesterone in CUB, and was significantly higher in luteal phase. RANKL and MYBPC1 mRNA expression were highly correlated between CUB and matched tumor samples. RANKL protein expression was also significantly increased in the luteal phase and highly correlated with serum progesterone levels in cancer samples, especially in hormone receptor positive tumors. The regulatory effects of progesterone on the expression of RANKL, DIO2, and MYBPC1 were confirmed in three-dimensional cultures of normal breast organoids. In normal breast and in breast cancer, RANKL mRNA and protein expression fluctuate with serum progesterone with highest levels in the luteal phase, suggesting that RANKL is a modulator of progesterone signaling in normal and malignant breast tissue and a potential biomarker of progesterone action and blockade.

Keywords

RANKL Progesterone Menstrual cycle Luteal phase 

Notes

Acknowledgments

This study was funded by the Lynn Sage Cancer Research Foundation, R01CA12055501, and a generous donation from Ms. Dariel Eklund. Additional support was provided by the Amgen Inc.

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

10549_2014_3049_MOESM1_ESM.pdf (1.1 mb)
Supplementary material 1 (PDF 1178 kb)

References

  1. 1.
    Obr AE, Edwards DP (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357:4–17PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Schramek D, Sigl V, Penninger JM (2011) RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 22:188–194PubMedCrossRefGoogle Scholar
  3. 3.
    Fernandez-Valdivia R, Lydon JP (2012) From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol 357:91–100PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Schneider P et al (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107:2989–2994PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R et al (2010) RANK ligand mediates progestin induced mammary epithelial proliferation and carcinogenesis. Nature 468:103–107PubMedCrossRefGoogle Scholar
  6. 6.
    Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98–102PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL et al (2010) Progesterone induces adult mammary stem cell expansion. Nature 465:803–807PubMedCrossRefGoogle Scholar
  8. 8.
    Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER et al (2010) Control of mammary stem cell function by steroid hormone signaling. Nature 465:798–802PubMedCrossRefGoogle Scholar
  9. 9.
    Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548–553PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Beral V (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362:419–427PubMedCrossRefGoogle Scholar
  11. 11.
    Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M (2006) Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer 118:1285–1291PubMedCrossRefGoogle Scholar
  12. 12.
    Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692PubMedCrossRefGoogle Scholar
  13. 13.
    Ferguson DJ, Anderson TJ (1981) Morphological evaluation of cell turnover in relation to the menstrual cycle in the ‘resting’ human breast. Br J Cancer 44:177–181PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Ferguson DJ (1988) An ultrastructural study of mitosis and cytokinesis in normal ‘resting’ human breast. Cell Tissue Res 252:581–587PubMedCrossRefGoogle Scholar
  15. 15.
    Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ (1989) Oral contraceptive use influences resting breast proliferation. Hum Pathol 20:1139–1144PubMedCrossRefGoogle Scholar
  16. 16.
    Anderson TJ, Ferguson DJ, Raab GM (1982) Cell turnover in the ‘resting’ human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 46:376–382PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Going JJ, Anderson TJ, Battersby S, MacIntyre CC (1988) Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130:193–204PubMedCentralPubMedGoogle Scholar
  18. 18.
    Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M et al (1988) The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58:163–170PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Bai M, Agnatis NJ, Kamina S, Demou A, Zagorianakou P, Katsaraki A et al (2001) In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res 3:276–283PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Feuerhake F, Sigg W, Höfter EA, Unterberger P, Welsch U (2003) Cell proliferation, apoptosis, and expression of Bcl-2 and Bax in non-lactating human breast epithelium in relation to the menstrual cycle and reproductive history. Breast Cancer Res Treat 77:37–48PubMedCrossRefGoogle Scholar
  21. 21.
    Capuco AV, Ellis S, Wood DL, Akers RM, Garrett W (2002) Postnatal mammary ductal growth: three-dimensional imaging of cell proliferation, effects of estrogen treatment, and expression of steroid receptors in prepubertal calves. Tissue Cell 34:143–154PubMedCrossRefGoogle Scholar
  22. 22.
    Clarke RB, Howell A, Potten CS, Anderson E (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987–4991PubMedGoogle Scholar
  23. 23.
    Russo J, Ao X, Grill C, Russo IH (1999) Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217–227PubMedCrossRefGoogle Scholar
  24. 24.
    Seagroves TN, Lydon JP, Hovey RC, Vonderhaar BK, Rosen JM (2000) C/EBPbeta (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. Mol Endocrinol 14:359–368PubMedGoogle Scholar
  25. 25.
    Rajaram RD, Brisken C (2012) Paracrine signaling by progesterone. Mol Cell Endocrinol 357:80–90PubMedCrossRefGoogle Scholar
  26. 26.
    Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI et al (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150:3318–3326PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF et al (2013) Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5(182):182ra55PubMedCrossRefGoogle Scholar
  28. 28.
    Ramakrishnan R, Khan SA, Badve S (2002) Morphological changes in breast tissue with menstrual cycle. Mod Pathol 15:1348–1356PubMedCrossRefGoogle Scholar
  29. 29.
    Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37–42PubMedCrossRefGoogle Scholar
  30. 30.
    Lee O, Helenowski IB, Chatterton RT, Jovanovic B, Khan SA (2012) Prediction of menopausal status from estrogen-related gene expression in benign breast tissue. Breast Cancer Res Treat 131:1067–1076PubMedCrossRefGoogle Scholar
  31. 31.
    Wang J, Gupta A, Hu H, Chatterton RT, Clevenger CV, Khan SA (2013) Comment on “Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5(215):215le4PubMedCrossRefGoogle Scholar
  32. 32.
    Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H et al (2013) Lipid metabolism genes in contralateral unaffected breast and estrogen receptor status of breast cancer. Cancer Prev Res 6:321–330CrossRefGoogle Scholar
  33. 33.
    Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S et al (2000) Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92:1217–1227PubMedCrossRefGoogle Scholar
  34. 34.
    Chatterton RT, Khan SA, Heinz R, Ivancic D, Lee O (2010) Patterns of sex steroid hormones in nipple aspirate fluid during the menstrual cycle and after menopause in relation to serum concentrations. Cancer Epidemiol Biomark Prev 19:275–279CrossRefGoogle Scholar
  35. 35.
    Burger HG, Dudley EC, Robertson DM, Dennerstein L (2002) Hormonal changes in the menopause transition. Recent Prog Horm Res 57:257–275PubMedCrossRefGoogle Scholar
  36. 36.
    Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, Stricker R (2006) Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med 44:883–887PubMedCrossRefGoogle Scholar
  37. 37.
    Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K et al (2013) Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res 15:R62PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Brisken C (2013) Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer 13:385–396PubMedCrossRefGoogle Scholar
  39. 39.
    Jankowitz RC, McGuire KP, Davidson NE (2013) Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. Breast 22:S165–S170PubMedCrossRefGoogle Scholar
  40. 40.
    Casula S, Bianco AC (2012) Thyroid hormone deiodinases and cancer. Front Endocrinol 3:74CrossRefGoogle Scholar
  41. 41.
    Debski MG, Pachucki J, Ambroziak M, Olszewski W, Bar-Andziak E (2007) Human breast cancer tissue expresses high level of type 1 5-deiodinase. Thyroid 17:3–10PubMedCrossRefGoogle Scholar
  42. 42.
    Dentice M, Luongo C, Huang S, Ambrosio R, Elefante A, Mirebeau-Prunier D et al (2007) Sonic hedgehog-induced type3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc Natl Acad Sci USA 104:14466–14471PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Chen Z, Zhao TJ, Li J, Gao YS, Meng FG, Yan YB et al (2011) Slow skeletal muscle myosin-binding protein-C (MyBPC1) mediates recruitment of muscle-type creatine kinase (CK) to myosin. Biochem J 436:437–445PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Hong Hu
    • 1
  • Jun Wang
    • 1
  • Akash Gupta
    • 1
  • Ali Shidfar
    • 1
  • Daniel Branstetter
    • 5
  • Oukseub Lee
    • 1
  • David Ivancic
    • 1
  • Megan Sullivan
    • 2
  • Robert T. ChattertonJr.
    • 3
    • 4
  • William C. Dougall
    • 6
  • Seema A. Khan
    • 1
    • 4
  1. 1.Department of SurgeryNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Department of PathologyNorthwestern University Feinberg School of MedicineChicagoUSA
  3. 3.Department of Obstetrics & GynecologyNorthwestern University Feinberg School of MedicineChicagoUSA
  4. 4.Robert H. Lurie Comprehensive Cancer CenterNorthwestern University Feinberg School of MedicineChicagoUSA
  5. 5.Department of PathologyAmgen, IncSeattleUSA
  6. 6.Therapeutic Innovation UnitAmgen, IncSeattleUSA

Personalised recommendations